Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer

Details for Australian Patent Application No. 2006324477 (hide)

International Classifications

Event Publications

26 June 2008 PCT application entered the National Phase

PCT publication WO2007/068895 Priority application(s): WO2007/068895

31 March 2011 Assignment before Grant

AstraZeneca AB The application has been assigned to MedImmune Limited

14 April 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.